More Sensitive Specific Scalable Liquid Biopsies

Our key technologies improve on existing approaches to liquid biopsy for several advantages in cancer detection. PointSuppressor™ (PSP) works seamlessly with any PCR-based assay to suppress unwanted wild type reads, lowering the limit of detection, increasing throughput, and decreasing sequencing costs by orders of magnitude. NexGenAbler™ (NGA) is a highly specific, sensitive, and automation-friendly method for quantitative measurement of mutations in cell-free DNA (cfDNA). MethylMarker™ enables measurement of methylation and mutation detection in the same tube. Each method substantially enhances liquid biopsy. Combined, these technologies will dramatically improve detection and monitoring of cancer.

RhoDx has developed a trifecta of technologies to enhance liquid biopsy and improve sensitivity, specificity, and scalability of cancer detection and monitoring. Explore the individual technologies for more information.

RhoDx has developed a trifecta of technologies to enhance liquid biopsy and improve sensitivity, specificity, and scalability of cancer detection and monitoring. Explore the individual technologies for more information.

PointSupressor Wild Type Suppression Example Data

Wild Type Suppression

  • Works with any primer-based assay
  • Suppresses unwanted reads
    • Dramatically decreases costs
    • Lowers limit of detection
  • Multiple variants can be detected at a site with just one assay
US Provisional Patent Filed 02FEB2021
NexGenAbler NGS Sample Prep Schematic

Mutation Detection

  • Single-tube method and Dynamic Molecular Index™ improves
    • Specificity
    • Sensitivity
    • Quantitation
  • Boundary Line™ for Tissue of Origin
Protected by US and European Patents
MethylMarker Illustrative method diagram

Methylation Detection

  • Entire sample available for both
    • Mutation detection
    • Methylation detection
  • Simple work flow keeps costs low
  • A second, independent method for Tissue of Origin (TOO)
US Provisional Patent Filed 10JUN2020